Should You be Optimistic on Neurocrine Biosciences (NBIX)?
PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Neurocrine Biosciences Inc (NBIX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 2,366,397 | $297,432,439 | -6% | 0.4% |
| 2. | Citadel Investment Group Ken Griffin | 2,049,075 | $257,548,237 | +131% | 0.04% |
| 3. | AQR Capital Management Cliff Asness | 1,510,015 | $189,793,729 | +41% | 0.16% |
| 4. | Millennium Management Israel Englander | 1,194,219 | $150,101,386 | +108% | 0.07% |
| 5. | Deerfield Management James E. Flynn | 1,167,802 | $146,781,033 | -22% | 2.66% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.96 | 22,300 | $132,796.50 | 3,527,700 | 2011-10-12 | Filing | |
| $5.96 | 1,000 | $5,955.00 | 757,600 | 2011-10-12 | Filing | |
| $5.96 | 6,200 | $36,921.00 | 1,236,665 | 2011-10-12 | Filing | |
| $5.73 | 3,800 | $21,768.30 | 3,505,400 | 2011-10-11 | Filing | |
| $5.59 | 44,700 | $249,779.13 | 3,501,600 | 2011-10-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $126.41 | 106,322 | $13,440,280.97 | 514,596 | 2025-08-07 | Filing | |
| $135.00 | 457 | $61,695.00 | 4,730 | 2025-07-10 | Filing | |
| $130.46 | 59,819 | $7,803,687.65 | 18,289 | 2025-07-09 | Filing | |
| $130.13 | 20,362 | $2,649,737.60 | 18,289 | 2025-07-02 | Filing | |
| $120.38 | 9,613 | $1,157,211.02 | 514,596 | 2025-05-27 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,202,756 | $168,842,887 | 0.57% | |
| 2. | 547,329 | $76,834,046 | 0.08% | |
| 3. | 382,441 | $52,394,417 | 0.08% | |
| 4. | 99,465 | $13,962,897 | 0.76% | |
| 5. | 98,423 | $13,816,621 | 0.09% |
News See All
What Does Wall Street Think About Neurocrine Biosciences (NBIX)?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc.
12 Best Drug Stocks to Buy Right Now
Dr. Marty stated that these ads are, by regulation, supposed to create a fair balance of information.
Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access
Neurocrine Biosciences, Inc.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's Neurocrine Biosciences Second Quarter 2025 Results Conference.
Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) develops therapies targeting neurological, neuroendocrine, and neuropsychiatric disorders.
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan Stanley raised the firm’s price target on Neurocrine Biosciences, Inc.
10 Best Strong Buy Healthcare Stocks to Buy Now
On July 21, Jared Holz, Mizuho health care sector strategist, appeared on CNBC's 'The Exchange' to talk about whether any opportunity plays exist within the healthcare sector, and what pains the sector...
11 Best Long Term Low Risk Stocks to Invest in
The uncertainty prevailing in the current market environment demands a closer examination beyond just earnings reports and share price trends when seeking a worthy investment.
Hedge Fund Resource Center Billionaire Hedge Funds
